Vlastimila Č.
- Country
- Czechia
- Department
- Onkologická klinika 2. LF UK a FN Motol
Research Overview
- Comparison of RO7771950 plus combination therapy versus tucatinib plus combination therapy in pretreated HER2-positive locally advanced or metastatic breast cancer
- Phase 3 Randomized Study of Sacituzumab Tirumotecan and Pembrolizumab Versus Physician's Choice in Triple-Negative Breast Cancer Post-Neoadjuvant Therapy
- Phase 3 Randomized, Double-Blind Study of Tucatinib with Trastuzumab and Pertuzumab in Maintenance Therapy for Metastatic HER2-Positive Breast Cancer
Data & Insights
Has run more than one trial at 94 of 285 partner sites.
Specializations
Breast Cancer Specialization
This investigator focuses on advanced therapeutic approaches for various types of breast cancer, with particular emphasis on hormone receptor-positive and HER2-negative variants.
- HR-positive/HER2-negative advanced breast cancer
- Metastatic breast cancer treatment
- Triple negative breast cancer
The investigator explores novel combination therapies for breast cancer patients at different disease stages.
Treatment Innovation
The investigator evaluates innovative therapeutic combinations including targeted therapies and hormone therapy approaches.
- Novel drug combinations with fulvestrant
- Letrozole-based treatment strategies
- Immunotherapy combinations
Research activities encompass both early-line and progressive disease treatment scenarios.
Clinical Expertise
The investigator's clinical focus includes systemic anticancer treatments and post-surgical therapeutic interventions.
- Advanced disease management
- Post-operative treatment strategies
- Progressive disease interventions
Expertise extends to both initial treatment approaches and management of disease progression.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.